Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Follicular Lymphoma · Marginal Zone Lymphoma · Mantle Cell Lymphoma · Diffuse Large B Cell Lymphoma · Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 97 (final count)
- Started
- Apr 29, 2020
- Main results expected
- Aug 28, 2024
- Fully finished
- Aug 28, 2024
- Results posted
- Feb 20, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: The Recommended Dose for Expansion (RDFE) of BGB-10188 Monotherapy in Hematologic Malignancies
Measured over: Up to 28 days
Part B: The RDFE of BGB-10188 in Combination With Zanubrutinib in Hematologic Malignancies
Measured over: Up to 28 days
Part D: The RDFE of BGB-10188 in Combination With Tislelizumab in Advanced Solid Tumors
Measured over: Up to 28 days
Part E: Overall Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1
Measured over: Up to 10.0 months
Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
Measured over: Part A: 47.2 Months; Part B: 24 Months; Part D: 15.2 Months; Part E: 10 Months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04282018 · record last updated 2026-02-20 · checked 2026-11-09 15:42 UTC